Core Viewpoint - Biodexa Pharmaceuticals PLC is providing an update on its financial position and the progress of its eRapa Phase 3 program, which targets Familial Adenomatous Polyposis (FAP) and highlights the significant market opportunity for its innovative treatments [2][3][7]. Financial Position - As of May 29, 2025, the company had cash resources totaling $10.1 million, which includes $5.7 million in cash at bank and $4.4 million in escrow for the eRapa Phase 3 program. Additionally, there is an undrawn CPRIT grant of $11.9 million for the same program, and the company has a debt of $0.5 million. The company projects sufficient working capital to fund operations into the first quarter of 2026 [3]. Issued Shares and Market Capitalization - The total number of ordinary shares outstanding as of May 29, 2025, is 50,506,308,922, equivalent to 5,050,630 American Depositary Shares (ADSs). The market capitalization based on the closing share price of $1.06 per ADS is approximately $5.4 million [4]. eRapa Phase 3 Program - The Phase 3 study of eRapa for FAP is in the final stages of implementation, involving a double-blind placebo-controlled trial with 168 patients, randomized in a 2:1 ratio of drug to placebo. The study will take place across approximately 30 clinical sites in the US and Europe, with recruitment expected to begin shortly [5]. About FAP - Familial Adenomatous Polyposis (FAP) is characterized by the proliferation of polyps in the colon and/or rectum, typically starting in mid-teens. There are currently no approved therapeutic options for FAP patients, making the development of eRapa particularly significant [6]. Market Opportunity - The addressable market for eRapa in FAP is estimated at approximately $7.3 billion, based on the lowest prevalence estimates in the US and Europe, with adult populations of approximately 258 million and 358 million, respectively. The median annual cost of approved non-biologic orphan drugs in the US is $206,176 [7]. About eRapa - eRapa is a proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor. It is designed to improve bioavailability and reduce toxicity associated with existing forms of rapamycin. Phase 2 study results indicated eRapa was safe and well-tolerated, showing a median 17% reduction in total polyp burden at 12 months compared to baseline [8].

Meriaura Group PlcCompany Announcement 30 May 2025 at 2.30 p.m. (CEST) The execution of the acquisition of Summa Defence Oy's share capital has begun, a new schedule Meriaura Group Oyj (“Company”) announced on January 29, 2025, that it had signed a conditional share exchange agreement to acquire all shares of Summa Defence Oy, which brings together companies in the defense and security sector, through a share exchange (“Share Exchange”). The Share Exchange is part of a broader arrangement, which includes th ...

Company Overview - Lead Real Estate Co., Ltd is a Japanese developer specializing in luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo [10] - The company also operates hotels in Tokyo and leases apartment units in Japan and Dallas, Texas [10] - The mission of the company is to provide stylish, safe, and luxurious living, while its vision focuses on continuous improvement and leveraging its strong market position in the luxury residential property market [11] Recent Developments - The company announced the signing of a sales contract for its planned luxury single-family home, REAL PRO Ookayama [1] - The REAL PRO SERIES Ookayama will be constructed from wood, featuring two floors above ground, with a building area of 2,029.3 square feet and a land area of 1,784.2 square feet [2] Location Highlights - Ookayama is known for its vibrant dining district, including the famous Ookayama Underground Dining Area, which has a nostalgic atmosphere reminiscent of the Showa Era [3][8] - The area is home to the prestigious Tokyo Institute of Technology, enhancing its appeal as a "Student Town" [5] - Ookayama Station provides direct access to major shopping districts, including Jiyugaoka and Futako-Tamagawa, both just 10 minutes away [5] Architectural Design - The architectural design of the REAL PRO SERIES is supervised by Pro Style Design Office Inc., known for its luxury architectural designs [6] - The design philosophy emphasizes creating high-density spaces that cater to the owner's lifestyle through the use of luxury brands in various aspects of living [6]

BONITA SPRINGS, Fla. and BATON ROUGE, La., May 30, 2025 (GLOBE NEWSWIRE) -- Herc Holdings Inc. (NYSE: HRI) (“Herc” or “the Company”) and H&E Equipment Services, Inc. d/b/a H&E Rentals (NASDAQ: HEES) (“H&E”) announced today the expiration of the tender offer to exchange each outstanding share of H&E common stock (the “H&E Shares”) for $78.75 in cash and 0.1287 shares of Herc common stock, in each case without interest (the “Offer”, and such consideration, the “Offer Price”), pursuant to the terms of the prev ...

BERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the Jefferies Global Healthcare Conference, taking place in New York on June 3 - 5, 2025. Jefferies Global Healthcare ConferenceDate:Thursday, June 5, 2025Time:3:45p.m. EDTFormat:PresentationWebcast:Link About CorMedix CorMedix Inc. is a biopharmaceutical company ...

All Shareholder Proposals Pass with Wide Margins Business Update Call Scheduled for June 5th at 10am PT OREM, Utah, May 30, 2025 (GLOBE NEWSWIRE) -- SunPower (aka Complete Solaria, Inc.) (“SunPower” or the “Company”) (Nasdaq: SPWR), a solar technology, services, and installation company, held its Annual Meeting yesterday, May 29th at 11:00 a.m. Pacific Time. All 12 SunPower proposals won with votes of 95% or higher, including: 1. the re-election of our 11 Board members, 2. re-hiring BDO as our auditor, and ...

TORONTO and TAMPA, Fla., May 30, 2025 (GLOBE NEWSWIRE) -- Voxtur Analytics Corp. (TSXV: VXTR; OTCQB: VXTRF) ("Voxtur" or the "Company"), a North American technology company creating a more transparent and accessible real estate lending ecosystem, today announced its financial results for the three months ended March 31, 2025. The Company's Unaudited Condensed Interim Consolidated Financial Statements and the related Management’s Discussion and Analysis (“MD&A”) for the three months ended March 31, 2025, are ...

Nasdaq OMX Copenhagen A/S Charlottenlund May 30, 2025 Announcement no. 277 Interim Report for the period January 1 – March 31, 2025 The Board of Directors has today reviewed and adopted the attached interim report for the period January 1 – March 31, 2025. The result before value adjustments and tax for the period January 1 – March 31, 2025, showed a profit of T.EUR 135.0. The result is considered as expected.The management assessed the property value in German properties at EUR 88.5 million as of March 31, ...

Core Insights - CERo Therapeutics has initiated its Phase 1 clinical trial for CER-1236, targeting acute myeloid leukemia (AML) with the first patient already dosed [1][3][4] - The trial is designed to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations, including those with relapsed/refractory disease and newly diagnosed patients with TP53 mutations [3][4] - The study will be presented at the 2025 Annual Meeting of the American Society of Clinical Oncology, highlighting the significance of this clinical milestone [1][4] Company Overview - CERo Therapeutics is focused on developing next-generation engineered T cell therapeutics, utilizing a proprietary approach that integrates characteristics of both innate and adaptive immunity [5] - The company aims to create Chimeric Engulfment Receptor T cells (CER-T) that can potentially treat both hematological malignancies and solid tumors, differentiating its product from existing CAR-T therapies [5] - The lead investigator for the trial is Dr. Abhishek Maiti from The University of Texas MD Anderson Cancer Center, who has collaborated with CERo on preclinical data publication [2][3]

Core Viewpoint - Australian Oilseeds Holdings Limited announced a A$5 million debt-to-equity conversion, enhancing its financial flexibility and reducing debt [1][3]. Group 1: Debt-to-Equity Conversion - JSKS Enterprises Pty Ltd., controlled by CEO Gary Seaton, converted approximately A$5 million of its outstanding loan into 4,452,479 shares of the Company's ordinary shares [2][3]. - The conversion will reduce the Company's debt by A$5 million and increase shareholders' equity by the same amount, aligning with the strategy to optimize capital structure [3]. Group 2: Company Overview - Australian Oilseeds Holdings Limited is focused on the manufacture and sale of sustainable oilseeds and is committed to eliminating chemicals from production processes [4]. - The Company operates the largest cold pressing oil plant in Australia, processing strictly GMO-free conventional and organic oilseeds [4].